Journal
MULTIPLE SCLEROSIS JOURNAL
Volume 22, Issue 6, Pages 770-781Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458515601903
Keywords
Multiple sclerosis; clinically isolated syndrome; blood-brain barrier; MRI; brain atrophy; disability
Categories
Funding
- Czech Ministry of Education [NT132374/2012, PRVOUK-P26/LF1/4, RVO-VFN64165/2012]
- Biogen Idec
- Czech Ministry of Health [NT132374/2012, PRVOUK-P26/LF1/4, RVO-VFN64165/2012]
Ask authors/readers for more resources
Background: The utility of blood-brain barrier (BBB) biomarkers for clinical and magnetic resonance imaging progression in multiple sclerosis (MS) has not been extensively investigated. Objectives: To determine whether cerebrospinal fluid (CSF) measures of BBB at clinical onset predict radiological and clinical deterioration over 48 months. Methods: This longitudinal study included 182 patients after first clinical event suggestive of MS treated with weekly intramuscular interferon beta-1a. CSF and serum samples were analyzed for leukocytes, total protein, albumin, immunoglobulins, and oligoclonal bands. Optimal thresholds for the albumin quotient (QAlb) were determined. Mixed-effect model analyses, adjusted for age, gender, and treatment escalation, were used to analyze relationship between CSF measures and disease activity outcomes over 48 months of follow-up. Results: Increased QAlb at clinical onset was associated with enlargement of lateral ventricles (p = .001) and greater whole brain (p = .003), white matter (p < .001), corpus callosum (p < .001), and thalamus (p = .003) volume loss over 48 months. Higher QAlb was associated with higher Expanded Disability Status Scale score over 48 months (p = .002). Conclusions: Increased QAlb at clinical onset is associated with increased brain atrophy and greater disability in patients after first clinical event suggestive of MS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available